Marrone Bio Innovations Inc. (NASDAQ:MBII) has been assigned a consensus rating of “Hold” from the six research firms that are presently covering the firm. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $5.06.

Separately, Zacks Investment Research upgraded shares of Marrone Bio Innovations from a “sell” rating to a “hold” rating in a report on Thursday, July 14th.

Shares of Marrone Bio Innovations (NASDAQ:MBII) opened at 1.66 on Thursday. The company’s market cap is $40.87 million. The firm’s 50-day moving average is $1.28 and its 200-day moving average is $0.96. Marrone Bio Innovations has a one year low of $0.60 and a one year high of $4.00.

Marrone Bio Innovations (NASDAQ:MBII) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.28) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.28). The business had revenue of $5 million for the quarter, compared to analysts’ expectations of $4.61 million. Marrone Bio Innovations had a negative net margin of 304.71% and a negative return on equity of 2,082.89%. On average, equities analysts anticipate that Marrone Bio Innovations will post ($1.12) EPS for the current year.

Marrone Bio Innovations Company Profile

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

5 Day Chart for NASDAQ:MBII

Receive News & Ratings for Marrone Bio Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.